Personal Finance
INO

Why Inovio Pharmaceuticals, Inc. Stock Is Jumping 12.4% Today

Gloved hands hold test tubes. Hand of person in blazer holds white cell phone displaying a question mark.

What happened

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) were up 12.4% as of 11:32 a.m. EDT on Wednesday. The stock's jump stemmed from the biotech's announcement of its second-quarter results after the market closed on Tuesday.

So what

Inovio is a clinical-stage biotech with no products on the market. The reality is that its financial results in a given quarter don't mean a lot. So why did the stock enjoy such a nice bounce?

Gloved hands hold test tubes. Hand of person in blazer holds white cell phone displaying a question mark.

Image source: Getty Images.

Investors were likely excited to hear about progress for Inovio's phase 3 Reveal 1 clinical study evaluating VGX-3100 in treating cervical dysplasia caused by the human papillomavirus (HPV). The company stated that enrollment is on track in this study, with 70 sites in 16 countries actively recruiting patients.

VGX-3100 presents Inovio's best chance for advancing a product to commercialization. It's the only pipeline candidate that Inovio currently has in phase 3 testing. Once the Reveal 1 study reaches full enrollment, Inovio plans to immediately begin its Reveal 2 confirmatory study.

If all goes well with these studies and Inovio ultimately wins regulatory approval for VGX-3100, it could have a big winner on its hands. Market research firm EvaluatePharma projects that the DNA immunotherapy could be one of the most valuable experimental vaccines in the biopharmaceutical industry.

Now what

It's great that Inovio is moving along nicely with its late-stage study of VGX-3100. The problem is that the biotech's studies of the immunotherapy won't fully wrap up until 2020. In the meantime, Inovio doesn't have steady revenue coming in the door and continues to burn through cash.

Inovio does have a remarkably deep pipeline for a clinical-stage biotech. However, these programs are either in phase 1 or phase 2 testing. The only revenue they might generate for Inovio is through collaborations. Unfortunately, this revenue won't be nearly enough to fund the company's operations.

This means that sooner or later Inovio will probably have to raise additional cash through a stock offering. When that happens, the biotech's share price is likely to drop -- just as it has in the past .

Inovio could be a big winner over the long run if VGX-3100 or its other pipeline candidates are successful. But there's no certainty that success will come. Inovio stock will probably be very volatile for a long time to come.

10 stocks we like better than Inovio Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Inovio Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 6, 2018

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INO

Other Topics

Stocks

Latest Personal Finance Videos

    #TradeTalks: The Changing E-Commerce Landscape

    e-Commerce Consultant James Thomson joins Jill Malandrino on Nasdaq #TradeTalks to discuss the changing e-commerce landscape, what consumers should prepare for as we head into shopping season and why you shouldn’t do last minute shipping.

    6 days ago

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More